Dermapharm Holding SE (FRA:DMP)
Market Cap | 2.12B |
Revenue (ttm) | 1.20B |
Net Income (ttm) | 113.79M |
Shares Out | n/a |
EPS (ttm) | 2.11 |
PE Ratio | 18.62 |
Forward PE | 16.71 |
Dividend | 0.90 (2.28%) |
Ex-Dividend Date | Jun 27, 2025 |
Volume | 14,693 |
Average Volume | 17,761 |
Open | 39.45 |
Previous Close | 39.35 |
Day's Range | 39.40 - 40.00 |
52-Week Range | 30.15 - 42.50 |
Beta | n/a |
RSI | 63.00 |
Earnings Date | May 15, 2025 |
About Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, France, Spain, Austria, Switzerland, and internationally. The company operates through three segments: Branded Pharmaceuticals, Other Healthcare Products, and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals. The company also provides vitamins, minerals, food supplements, as well as product... [Read more]
Financial Performance
In 2024, Dermapharm Holding SE's revenue was 1.20 billion, an increase of 3.89% compared to the previous year's 1.15 billion. Earnings were 113.79 million, an increase of 82.44%.
Financial StatementsNews

EQS-PVR: Dermapharm Holding SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Dermapharm Holding SE Dermapharm Holding SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wid...

EQS-DD: Dermapharm Holding SE: Susanne Gertrud Pia Lanz, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 08.04.2025 / 16:43 CET/CEST The issuer is solely responsi...

Dermapharm's 2024: Revenue Soars, Surpassing EBITDA Expectations
Dermapharm's financial results for 2024 reflect a dynamic year of growth and strategic adjustments, setting a promising stage for the future. Jetzt den vollständigen Artikel lesen

EQS-News: Successful financial year 2024: Dermapharm increases revenue and exceeds EBITDA guidance
EQS-News: Dermapharm Holding SE / Key word(s): Annual Results/Annual Report Successful financial year 2024: Dermapharm increases revenue and exceeds EBITDA guidance 28.03.2025 / 07:30 CET/CEST The iss...

EQS-DD: Dermapharm Holding SE: Themis Beteiligungs-Aktiengesellschaft, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 18.03.2025 / 13:12 CET/CEST The issuer is solely responsi...

Dermapharm Surpasses EBITDA Forecast with Revenue Boost
Dermapharm Holding SE's financial prowess shines with a 4% revenue boost, driven by 'Branded pharmaceuticals,' and a 10.2% EBITDA surge, setting the stage for promising growth in 2025. Jetzt den volls...

EQS-News: Dermapharm Holding SE increases revenue as projected and exceeds guidance for adjusted consolidated EBITDA
EQS-News: Dermapharm Holding SE / Key word(s): Annual Results/Preliminary Results Dermapharm Holding SE increases revenue as projected and exceeds guidance for adjusted consolidated EBITDA 14.03.2025 ...